Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 5, 2008, Pages 1511-1525

  Ruggenenti, Piero ^a,b   Bettinaglio, Paola ^a   Pinares, Franck ^a   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; ENZYMOLOGY; GENETICS; GENOTYPE; HUMAN; INSERTION DELETION MUTATION; KIDNEY DISEASE; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GENOTYPE; HUMANS; INDEL MUTATION; KIDNEY DISEASES; PATIENT SELECTION; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; PHENOTYPE; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 53749103611     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04140907     Document Type: Review

References (100)

1. Tigerstedt R, Bergman P: Niere und Kreislauf. Skan Arch Physiol 8: 223-271, 1898
2. Goldblatt H: Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59: 347, 1934
3. Braun-Menendez E, Page JH: Suggested revision of nomenclature-angiotensin. Science 127: 242, 1958
4. Skeggs LT Jr, Marsh WH, Kahn JR, Shumway NP: The purification of hypertensin I. J Exp Med 100: 363-370, 1954
5. Skeggs LT Jr, Marsh WH, Kahn JR, Shumway NP: The existence of two forms of hypertensin. J Exp Med 99: 275-282, 1954
6. Skeggs LT Jr, Kahn JR, Shumway NP: The preparation and function of the hypertensin-converting enzyme. J Exp Med 103: 295-299, 1956
7. Skeggs LT Jr, Lentz KE, Kahn JR, Shumway NP, Woods KR: The amino acid sequence of hypertensin. II. J Exp Med 104: 193-197, 1956
8. Elliott DF, Peart WS: Amino-acid sequence in a hypertensin. Nature 177: 527-528, 1956
9. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP: The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 106: 439-453, 1957
10. Goodfriend TL, Lin SY: Receptors for angiotensin I and II. Circ Res 27: 163-174, 1970
11. Navar LG, Rosivall L: Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. Kidney Int 25: 857-868, 1984
12. Raij L, Keane WF: Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 79: 24-30, 1985
13. Anderson S, Brenner BM: The role of intraglomerular pressure in the initiation and progression of renal disease. J Hypertens 4[Suppl]: 236-238, 1986
14. Anderson PW, Do YS, Hsueh WA: Angiotensin II causes mesangial cell hypertrophy. Hypertension 21: 29-35, 1993
15. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384-394, 1990
16. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346, 1990
17. Jacobsen PK: Preventing end stage renal disease in diabetic patients: genetic aspect (part I). J Renin Angiotensin Aldosterone Syst 6: 1-14, 2005
18. Ng DP, Tai BC, Koh D, Tan KW, Chia KS: Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 48: 1008-1016, 2005
19. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney Int 57: 274-281, 2000
20. Pereira TV, Nunes AC, Rudnicki M, Magistroni R, Albertazzi A, Pereira AC, Krieger JE: Influence of ACE I/D gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease: a meta-analysis. Nephrol Dial Transplant 21: 3155-3163, 2006
21. Yong D, Qing WQ, Hua L, Kan JJ, Xi CJ, Jin QQ, Chao SH: Association of angiotensin I-converting enzyme gene insertion/deletion polymorphism and IgA nephropathy: a meta-analysis. Am J Nephrol 26: 511-518, 2006
22. Niu T, Chen X, Xu X: Angiotensin converting enzyme gene insertion/ deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs 62: 977-993, 2002
23. Ondetti MA, Rubin B, Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441-444, 1977
24. Buhler FR, deLeeuw PW, Doyle AE, Fleckenstein A, Fleckenstein-Grun G, Frishman WH, Zanchetti A: Proceedings of a symposium: calcium metabolism and calcium channel blockers for understanding and treating hypertension. Am J Med 77: 1-23, 1984
25. Wang Y, Ng MC, So WY, Tong PC, Ma RC, Chow CC, Cockram CS, Chan JC: Prognostic effect of insertion/deletion polymorphism of the ace gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care 28: 348-354, 2005
26. Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop PH, Parving HH, Cambien F, Tregouet DA, Gut IG, Theva A, Gauguier D, Farrall M, Cox R, Matsuda F, Lathrop M, Hager-Vionnet N: Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol 18: 1284-1291, 2007
27. Marre M, Bouhanick B, Berrut G, Gallois Y, Le Jeune JJ, Chatellier G, Menard J, Alhenc-Gelas F: Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes. Hypertension 33: 775-780, 1999
28. Ito S, Arima S, Ren YL, Juncos LA, Carretero OA: Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 91: 2012-2019, 1993
29. Sasse B, Hailemariam S, Wuthrich RP, Kemper MJ, Neuhaus TJ: Angiotensin converting enzyme gene polymorphisms do not predict the course of idiopathic nephrotic syndrome in Swiss children. Nephrology (Carlton) 11: 538-541, 2006
30. Tsai IJ, Yang YH, Lin YH, Wu VC, Tsau YK, Hsieh FJ: Angiotensin-converting enzyme gene polymorphism in children with idiopathic nephrotic syndrome. Am J Nephrol 26:157-162, 2006
31. Serdaroglu E, Mir S, Berdeli A, Aksu N, Bak M: ACE gene insertion/ deletion polymorphism in childhood idiopathic nephrotic syndrome. Pediatr Nephrol 20: 1738-1743, 2005
32. Oktem F, Sirin A, Bilge I, Emre S, Agachan B, Ispir T: ACE I/D gene polymorphism in primary FSGS and steroid-sensitive nephrotic syndrome. Pediatr Nephrol 19: 384-389, 2004
33. Luther Y, Bantis C, Ivens K, Fehsel K, Kolb-Bachhofen V, Heering P: Effects of the genetic polymorphisms of the renin-angiotensin system on focal segmental glomerulo-sclerosis. Kidney Blood Press Res 26: 333-337, 2003
34. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
35. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, Remuzzi G: Chronic proteinuric nephropathies: II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (GISEN). J Am Soc Nephrol 11: 88-96, 2000
36. Samuelsson O, Attman PO, Larsson R, Mulec H, Rymo L, Weiss L, Ricksten A: Angiotensin I-converting enzyme gene polymorphism in non-diabetic renal disease. Nephrol Dial Transplant 15: 481-486, 2000
37. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 347: 94-95, 1996
38. Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P: Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int 60: 46-54, 2001
39. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong LA, Fuller JH: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 47: 1507-1511, 1998
40. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH: Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 14: 2843-2850, 2003
41. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gone on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 313: 591-594, 1996
42. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O, Cambien F, Parving HH: Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 53. 1002-1006, 1998
43. Weekers L, Bouhanick B, Hadjadj S, Gallois Y, Roussel R, Pean F, Ankotche A, Chatellier G, Alhenc-Gelas F, Lefebvre PJ, Marre M: Modulation of the renal response to ACE inhibition by ACE insertion/ deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes 54: 2961-2967, 2005
44. So WY, Ma RC, Ozaki R, Tong PC, Ng MC, Ho CS, Lam CW, Chow CC, Chan WB, Kong AP, Chan JC: Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients: interaction with ACE insertion/deletion polymorphism. Kidney Int 69: 1438-1443, 2006
45. Ha SK, Yong Lee S, Su Park H, Ho Shin J, Jung Kim S, Hun Kim D, Rae Kim K, Yung Lee H, Suk Han D: ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrol Dial Transplant 15: 1617-1623, 2000
46. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH: Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26: 1501-1506, 2003
47. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH: Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 62: 11,92-198, 2002
48. Haneda M, Kikkawa R, Sakai H, Kawamori R: Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 66: 87-95, 2004
49. Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S: The losartan renal protection study: rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 1: 328-335, 2000
50. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, Shahinfar S, Wong PH, Lyle PA, Rossing P, Brenner BM: ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 19: 771-779, 2008
51. Han SY, Kwon YJ, Jo SK, Shin JH, Cha DR, Cho WY, Pyo HJ, Kim HK: ACE gene polymorphism and renal responsiveness to ACE inhibitors in IgA nephropathy patients. Korean J Intern Med 15: 13-18, 2000
52. Kutyrina IM, Tareeva IE, Nosikov VV, Kamyshova ES, Gorashko NM, Chistiakov DA, Okonova. EB, Troepol'skaia OV: [Polymorphism. studies of angiotensin converting enzyme gene in chronic glomerulonephritis]. Ter Arkh 71: 30-34,1999
53. Liu J, Wang M, Liu Q, Li Y, Peng B: [Influence of angiotensin-converting enzyme gene polymorphism. on the anti-proteinuria efficacy of angiotensin-converting enzyme inhibitor in Han nationality of southern Sichuan province in China]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22: 204 -205, 2005
54. Moriyama T, Kitamura H, Ochi S, Izumi M, Yokoyama K, Yamauchi A, Ueda N, Kamada. T, Imai E: Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 6: 1676-1678, 1995
55. Yoshida H, Mitarai T, Kawamura T, Kitajima T, Miyazaki Y, Nagasawa R, Kawaguchi Y, Kubo H, Ichikawa I, Sakai O: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 96: 2162-2169, 1995
56. van der Kleij FG, Navis GJ, Gansevoort RT, Heeg JE, Schef fer H, de Zeeuw D, de Jong PE: ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients. Nephrol Dial Transplant 12[Suppl 2]: 42-46,1997
57. van der Kleij FG, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, Mayer G, de Zeeuw D: Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status. Kidney Int 63[Suppl 2]: 23-26, 1997
58. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll. HK, Wallner M, Auinger M, Arias I, Schneider B, Mayer G: Angiotensin-converting enzyme gene polymorphism. determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease: Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 21: 66-69, 1998
59. van der Kleij FG, de Jong PE, Henning RH, de Zeeuw D, Navis G: Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 13: 1025-1033, 2002
60. Coto E, Marin R, Alvarez V, Praga M, Fernandez Andrade C, Arias M, Poveda R, Valles M, Galceran JM, Luno J, Rivera F, Campistol JM: [Pharmacogenetics of angiotensin system in non diabetic nephropathyl. Nefrologia 25: 381-386, 2005
61. Redon J, Luque-Otero M, Martell N, Chaves FJ: Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 5: 14-20, 2005
62. Park HC, Choi HY, Kim BS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS: Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism. Kidney Blood Press Res 29: 216 -224, 2006
63. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, et al: Molecular basis of human hypertension: role of angiotensinogen. Cell 71: 169-180, 1992
64. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X, Lalouel JM: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99: 1786-1797, 1997
65. Freire MB, Ji L, Onuma T, Orban T, Warram JH, Krolewski AS: Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. Hypertension 31: 896-899, 1998
66. Rogus JJ, Moczulski D, Freire MB, Yang Y, Warram JH, Krolewski AS: Diabetic nephropathy is associated with AGT polymorphism T235: results of a family-based study. Hypertension 31: 627-631, 1998
67. Brand E, Chatelain N, Paillard F, Tiret L, Visvikis S, Lathrop M, Soubrier F, Demenais F: Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage anal ysis. Eur J Hum Genet 10: 715-723, 2002
68. Reyes-Engel A, Morcillo L, Aranda FJ, Ruiz M, Gaitan MJ, Mayor-Olea A, Aranda P, Ferrario CM: Influence of gender and genetic variability on plasma angiotensin peptides. J Renin Angiotensin Aldosterone Syst 7: 92-97, 2006
69. Zychma MJ, Zukowska-Szczechowska E, Lacka BI, Grzeszczak W: Angiotensinogen M235T and chymase gene CMA/B polymorphisms are not associated with nephropathy in type II diabetes. Nephrol Dial Transplant 15: 1965-1970, 2000
70. Fradin S, Goulet-Salmon B, Chantepie M, Grandhomme F, Morello R, Jauzac P, Reznik Y: Relationship between polymorphisms in the renin-angiotensin system and nephropathy in type 2 diabetic patients. Diabetes Metab 28: 27-32, 2002
71. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 12: 541-549, 2001
72. Buraczynska M, Ksiazek P, Drop A, Zaluska. W, Spasiewicz D, Ksiazek A: Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant 21: 979-983, 2006
73. Woo KT, Lau YK, Choong LH, Zhao Y, Tan HB, Fook-Chong S, Tan EK, Yap HK, Wong KS: Polymorphism of renin-angiotensin system genes in IgA nephropathy. Nephrology (Carlton) 9: 304-309, 2004
74. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F: Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24: 63-69, 1994
75. Wang WY, Zee RY, Morris BJ: Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Clin Genet 51: 31-34, 1997
76. Tiret L, Blanc H, Ruidavets JB, Arveiler D, Luc G, Jeunemaitre X, Tichet J, Mallet C, Poirier O, Plouin PF, Cambien F: Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: the PEGASE study. Projet d'Etude des Genes de l'Hypertension Arterielle Severe a moderee Essentielle. J Hypertens 16: 37-44, 1998
77. Buraczynska M, Ksiazek P, Lopatynski J, Spasiewicz D, Nowicka T, Ksiazek A: [Association of the renin-angiotensin system gene polymorphism with nephropathy in type II diabetes]. Pol Arch Med Wewn 108: 725-730, 2002
78. Tomino Y, Makita Y, Shike T, Gohda T, Haneda M, Kikkawa R, Watanabe T, Baba T, Yoshida H: Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron 82: 139-144, 1999
79. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, Kubo H, Kawaguchi Y, Kon V, Matsuoka K, Ichikawa I, Sakai O: Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 50: 657-664, 1996
80. Maruyama K, Yoshida M, Nishio H, Shirakawa T, Kawamura T, Tanaka R, Nakamura H, Iijima K, Yoshikawa N: Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy. Pediatr Nephrol 16: 350-355, 2001
81. Hunley TE, Julian BA, Phillips JA 3rd, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V: Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 49: 571-577, 1996
82. Konoshita T, Miyagi K, Onoe T, Katano K, Mutoh H, Nomura H, Koni I, Miyamori I, Mabuchi H: Effect of ACE gene polymorphism on age at renal death in polycystic kidney disease in Japan. Am J Kidney Dis 37: 113-118, 2001
83. Baboolal K, Ravine D, Daniels J, Williams N, Holmans P, Coles GA, Williams JD: Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 52: 607-613, 1997
84. Marrè M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 99: 1585-1595, 1997
85. Bantis C, Ivens K, Kreusser W, Koch M, Klein-Vehne N, Grabensee B, Heering P: Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy. Am J Nephrol 24: 258-267, 2004
86. Osawa N, Koya D, Araki S, Uzu T, Tsunoda T, Kashiwagi A, Nakamura Y, Maeda S: Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Genet 52: 143-151, 2007
87. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992
88. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE: A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 2: 41-45, 1996
89. Morita T, Ito H, Suehiro T, Tahara K, Matsumori A, Chikazawa H, Nakauchi Y, Nishiya K, Hashimoto K: Effect of a polymorphism of endothelial nitric oxide synthase gene in Japanese patients with IgA nephropathy. Clin Nephrol 52: 203-209, 1999
90. Burg M, Menne J, Ostendorf T, Kliem V, Floege J: Gene-polymorphisms of angiotensin converting enzyme and endothelial nitric oxide synthase in patients with primary glomerulonephritis. Clin Nephrol 48: 205-211, 1997
91. Stratta P, Bermond F, Guarrera S, Canavese C, Carturan S, Dall'Omo A, Ciccone G, Bertola L, Mazzola G, Fasano E, Matullo G: Interaction between gene polymorphisms of nitric oxide synthase and renin-angioteosin system in the progression of membranous glomerulonephritis. Nephrol Dial Transplant 19: 587-595, 2004
92. Salardi S, Saccardo B, Borsani G, Modica R, Ferrandi M, Tripodi MG, Soria M, Ferrari P, Baralle PE, Sidoli A, et al: Erythrocyte adducin differential properties in the normotensive and hypertensive rats of the Milan strain: characterization of spleen adducin mRNA. Am J Hypertens 2: 229-237, 1989
93. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, Leoni P, Torielli L, Cusi D, Ferrandi M, et al: Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci U S A 91: 3999-4003, 1994
94. Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhager WH, Herrmann SM, Fagard R, Tizzoni L, Bianchi G: Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens 19: 1349-1358, 2001
95. Pedrinelli R, Dell'Omo G, Penno G, Di Bello V, Pucci L, Fotino C, Lucchesi D, Del Prato S, Dal Fiume C, Barlassina C, Cusi D: Alpha-adducin and angiotensin-converting enzyme polymorphisms in hypertension: evidence for a joint influence on albuminuria. J Hypertens 24: 931-937, 2006
96. Wang JG, Staessen JA, Tizzoni L, Brand E, Birkenhager WH, Fagard R, Herrmann SM, Bianchi G: Renal function in relation to three candidate genes. Am J Kidney Dis 38: 1158-1168, 2001
97. Narita I, Goto S, Saito N, Song J, Ajiro J, Sato F, Saga D, Kondo D, Akazawa K, Sakatsume M, Gejyo F: Interaction between ACE and ADD1 gene polymorphisms in the progression of IgA nephropathy in Japanese patients. Hypertension 42: 304-309, 2003
98. Schieppati A, Perico N, Remuzzi G: Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. Nephrol Dial Transplant 18: 858-859, 2003; discussion 857
99. Costa-Scharplatz M, van Asselt AD, Bachmann LM, Kessels AG, Severens JL: Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Pharmacogenet Genomics 17: 359-368, 2007
100. Hoy WE, Baker PR, Kelly AM, Wang Z: Reducing premature death and renal failure in Australian aboriginals: a community-based cardiovascular and renal protective program. Med J Aust 172: 473-478, 2000